Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene.
The prototypical member of the vanilloid-responsive-like subfamily of transient receptor potential (TRP) channels is TRPV1. TRPV1 mediates aspects of nociception and neurogenic inflammation; however, new roles are emerging in sensation of both luminal stretch and systemic tonicity. Although at least six nonsynonymous polymorphisms in the human TRPV1 gene have been identified, there has been no systematic investigation into their functional consequences. When heterologously expressed in HEK293 cells, all variants exhibited equivalent EC(50) for the classic agonist capsaicin. This agonist elicited a greater maximal response in TRPV1(I315M) and TRPV1(P91S) variants (relative to TRPV1(WT)), as did a second agonist, anandamide. Expression of these two variants in whole-cell lysates and at the cell surface was markedly greater than that of wild-type TRPV1, whereas expression at the mRNA level was either unchanged (TRPV1(P91S)) or only very modestly increased (TRPV1(I315M)). Incorporation of multiple nonsynonymous SNPs, informed by the population-specific haplotype block structure of the TRPV1 gene, did not lead to variant channels with unique features vis-à-vis capsaicin responsiveness. Recently, polymorphisms/mutations were identified in two highly conserved TRPV1 residues in the nonobese diabetic (NOD) murine model. Incorporation of these changes into human TRPV1 gave rise to a channel with a normal EC(50) for capsaicin, but with a markedly elevated Hill slope such that the variant channel was hyporesponsive to capsaicin at low doses (<10 nM) and hyperresponsive at high doses (>10 nM). In aggregate, these data underscore expression-level and functional differences among naturally occurring TRPV1 variants; the implications with respect to human physiology are considered.
Xu
Hongshi
H
Oregon Health and Science University, 3314 S.W. US Veterans Hospital Rd., Portland, OR 97201, USA.
Tian
Wei
W
Fu
Yi
Y
Oyama
Terry T
TT
Anderson
Sharon
S
Cohen
David M
DM
D001095:Arachidonic Acids / Q000494:pharmacology; D001710:Biotin; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002211:Capsaicin / Q000494:pharmacology; D045744:Cell Line, Tumor; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D015870:Gene Expression / Q000187:drug effects; D014644:Genetic Variation / Q000187:drug effects; D006801:Humans; D007091:Image Processing, Computer-Assisted; D023282:Nuclease Protection Assays; D011110:Polymorphism, Genetic / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D053284:Polyunsaturated Alkamides / Q000494:pharmacology; D050916:TRPV Cation Channels / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D014162:Transfection
D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D001710:Biotin; D002211:Capsaicin; D002118:Calcium; C078814:anandamide